iiinova — where your digital self keeps evolving

David Fabregat @davidfabregat.bsky.social · 23/04/2026

📢 Publication alert! Just published in #EnvironmentInternational! This article discusses the limitations on #amoxicillin detection, its rapid degradation in the environment, and suggest a new marker for amoxicillin consumption! You can freely access the paper: www.sciencedirect.com/science/arti...

sciencedirect.com

Can amoxicillin be detected in the aquatic environment? A critical assessment

Amoxicillin is a broad-spectrum β-lactam antibiotic widely used in both human and veterinary medicine. Following administration, approximately 60–80% …

010

David Fabregat @davidfabregat.bsky.social · 25/11/2025

📜It has been a pleasure to collaborate in this highly interesting study published in @commsbio.nature.com! 🎉Congrats @gmallaret.bsky.social and colleagues! 🔜And more to come from the collaboration bewteen Laetitia Davidovic's research group and Applied Metabolomics at @researchmar.bsky.social.

031

David Fabregat @davidfabregat.bsky.social · 24/11/2025

👍 Future works should ideally satisfy all the steps outlined to ensure confidence in the metabolites found to be significant for a specific cancer . They should clearly indicate their limitations by specifying the workflow steps completed and those that require further research.

000

David Fabregat @davidfabregat.bsky.social · 24/11/2025

🤔 The analytical laboratories working on MS-based metabolomics for clinical applications should consider that they are providing crucial data for medical researchers, being aware of the need of providing robust results to cancer research.

100

David Fabregat @davidfabregat.bsky.social · 24/11/2025

💡 With the main objective of favouring the standardization, we propose a workflow for the establishment of cancer biomarkers which includes different pivotal steps and issues that must be carefully evaluated for maximizing robustness and reliability on the proposed biomarkers.

100

David Fabregat @davidfabregat.bsky.social · 24/11/2025

📜 One of the key aspects is the need for a consensus in MS-based metabolomics for the discovery of clinical biomarkers and their implementation for the early-diagnosis of cancer.

100

David Fabregat @davidfabregat.bsky.social · 24/11/2025

📝 In this study, we identified the most critical aspects of the metabolomics workflow that should be carefully addressed in future mass spectrometry-based metabolomics studies in cancer diagnosis.

100

David Fabregat @davidfabregat.bsky.social · 24/11/2025

🤝 This thorough and critical review of the MS-based metabolomics studies for cancer biomarker of the last 7 years has been possible thanks to the strong collaboration, passion and dedication of different researchers from Applied #Metabolomics research group and @researchmar.bsky.social.

100

David Fabregat @davidfabregat.bsky.social · 24/11/2025

📢 NEW PUBLICATION ALERT!! 😍 I'm extremely glad to share with all of you our new publication in TrAC-Trends in Analytical Chemistry @elsevierconnect.bsky.social. 🌐 Feel free to download the publication (open access) from the folllowing link: sciencedirect.com/science/arti... 🧵 Summary thread:

sciencedirect.com

Lights and shadows of mass spectrometry-based metabolomics studies in cancer diagnosis: is there any marker beyond the literature background noise?

Mass spectrometry (MS)-based metabolomics is considered as one of the gold-standards for the discovery of clinical biomarkers. However, metabolites pr…

150